KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

TherapeuticsMD (TXMD) EBITDA Margin: 2010-2025

Historic EBITDA Margin for TherapeuticsMD (TXMD) over the last 15 years, with Sep 2025 value amounting to -109.95%.

  • TherapeuticsMD's EBITDA Margin rose 9736.00% to -109.95% in Q3 2025 from the same period last year, while for Sep 2025 it was -61.80%, marking a year-over-year increase of 31088.00%. This contributed to the annual value of -270.30% for FY2024, which is 51910.00% up from last year.
  • Per TherapeuticsMD's latest filing, its EBITDA Margin stood at -109.95% for Q3 2025, which was down 50.61% from -73.00% recorded in Q2 2025.
  • In the past 5 years, TherapeuticsMD's EBITDA Margin ranged from a high of 32,264.66% in Q2 2022 and a low of -8,182.20% during Q3 2022.
  • For the 3-year period, TherapeuticsMD's EBITDA Margin averaged around -911.97%, with its median value being -221.63% (2025).
  • Its EBITDA Margin has fluctuated over the past 5 years, first spiked by 3,245,009bps in 2022, then slumped by 3,281,706bps in 2023.
  • TherapeuticsMD's EBITDA Margin (Quarterly) stood at -230.00% in 2021, then soared by 34,333bps to 113.32% in 2022, then tumbled by 28,922bps to -175.90% in 2023, then skyrocketed by 28,084bps to 104.95% in 2024, then skyrocketed by 9,736bps to -109.95% in 2025.
  • Its EBITDA Margin was -109.95% in Q3 2025, compared to -73.00% in Q2 2025 and -221.63% in Q1 2025.